; Type 2 Diabetes – Pipeline Review, H1 2012
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Type 2 Diabetes – Pipeline Review, H1 2012

VIEWS: 7 PAGES: 282

Type 2 Diabetes - Pipeline Review, H1 2012', provides an overview of the Type 2 Diabetes therapeutic pipeline. This report provides information on the therapeutic development for Type 2 Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Type 2 Diabetes. 'Type 2 Diabetes - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
  • pg 1
									                  Type 2 Diabetes – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1726IDB
                                                                                           Publication Date: February 2012




Type 2 Diabetes – Pipeline Review, H1 2012                                                 GMDHC1726IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Type 2 Diabetes – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 8
    List of Figures .............................................................................................................................................................................. 13
Introduction....................................................................................................................................................................................... 14
    Global Markets Direct Report Coverage ...................................................................................................................................... 14
Type 2 Diabetes Overview ............................................................................................................................................................... 15
Therapeutics Development............................................................................................................................................................... 16
    An Overview of Pipeline Products for Type 2 Diabetes ............................................................................................................... 16
Type 2 Diabetes Therapeutics under Development by Companies.................................................................................................. 18
Type 2 Diabetes Therapeutics under Investigation by Universities/Institutes ................................................................................... 31
Late Stage Products ......................................................................................................................................................................... 35
    Comparative Analysis .................................................................................................................................................................. 35
Mid Clinical Stage Products.............................................................................................................................................................. 36
    Comparative Analysis .................................................................................................................................................................. 36
Early Clinical Stage Products ........................................................................................................................................................... 37
    Comparative Analysis .................................................................................................................................................................. 37
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 38
    Comparative Analysis .................................................................................................................................................................. 38
Type 2 Diabetes Therapeutics – Products under Development by Companies................................................................................ 39
Type 2 Diabetes Therapeutics – Products under Investigation by Universities/Institutes ................................................................. 60
Companies Involved in Type 2 Diabetes Therapeutics Development .............................................................................................. 64
    Bristol-Myers Squibb Company ................................................................................................................................................... 64
    Johnson & Johnson ..................................................................................................................................................................... 65
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 66
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 67
    Abbott Laboratories ..................................................................................................................................................................... 68
    Shionogi & Co., Ltd...................................................................................................................................................................... 69
    NsGene A/S................................................................................................................................................................................. 70
    Amgen Inc. .................................................................................................................................................................................. 71
    Sanofi-Aventis ............................................................................................................................................................................. 72
    AstraZeneca PLC ........................................................................................................................................................................ 73
    Eli Lilly and Company .................................................................................................................................................................. 74
    GlaxoSmithKline plc .................................................................................................................................................................... 75
    MedImmune LLC ......................................................................................................................................................................... 76
    Isis Pharmaceuticals, Inc. ............................................................................................................................................................ 77
    Gilead Sciences, Inc. ................................................................................................................................................................... 78
    Daiichi Sankyo Company, Ltd...................................................................................................................................................... 79
    Merck & Co., Inc. ......................................................................................................................................................................... 80
    Dainippon Sumitomo Pharma Co., Ltd. ....................................................................................................................................... 81
    Taisho Pharmaceutical Co., Ltd................................................................................................................................................... 82
    Euroscreen S.A. .......................................................................................................................................................................... 83
    Novo Nordisk A/S ........................................................................................................................................................................ 84



Type 2 Diabetes – Pipeline Review, H1 2012                                                                                                 GMDHC1726IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Type 2 Diabetes – Pipeline Review, H1 2012




    Generex Biotechnology Corporation............................................................................................................................................ 85
    Takeda Pharmaceutical Company Limited .................................................................................................................................. 86
    BioLineRx, Ltd. ............................................................................................................................................................................ 87
    Senexis Limited ........................................................................................................................................................................... 88
    Neurocrine Biosciences, Inc. ....................................................................................................................................................... 89
    Novartis AG ................................................................................................................................................................................. 90
    Amylin Pharmaceuticals, Inc........................................................................................................................................................ 91
    Astellas Pharma Inc..................................................................................................................................................................... 92
    Biocon Limited ............................................................................................................................................................................. 93
    Chong Kun Dang Pharmaceutical ............................................................................................................................................... 94
    Chugai Pharmaceutical Co. Ltd ................................................................................................................................................... 95
    Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 96
    Forest Laboratories, Inc............................................................................................................................................................... 97
    Glenmark Pharmaceuticals Ltd.................................................................................................................................................... 98
    Hanmi Pharmaceutical Co Ltd ..................................................................................................................................................... 99
    Japan Tobacco Inc. ................................................................................................................................................................... 100
    Kissei Pharmaceutical Co., Ltd. ................................................................................................................................................. 101
    Mitsubishi Tanabe Pharma Corporation .................................................................................................................................... 102
    MDRNA, Inc............................................................................................................................................................................... 103
    Pfizer Inc.................................................................................................................................................................................... 104
    Rigel Pharmaceuticals, Inc. ....................................................................................................................................................... 105
    Sigma-Tau S.p.A. ...................................................................................................................................................................... 106
    VIVUS, Inc. ................................................................................................................................................................................ 107
    Zydus Cadila Healthcare Limited ............................................................................................................................................... 108
    Hadasit Medical Research Services & Development Ltd........................................................................................................... 109
    TransPharma Medical Ltd. ........................................................................................................................................................ 110
    Biodel Inc. .................................................................................................................................................................................. 111
    Incyte Corporation ..................................................................................................................................................................... 112
    MannKind Corporation............................................................................................................................................................... 113
    Halozyme Therapeutics ............................................................................................................................................................. 114
    Addex Pharmaceuticals ............................................................................................................................................................. 115
    Evotec Aktiengesellschaft.......................................................................................................................................................... 116
    GW Pharmaceuticals plc ........................................................................................................................................................... 117
    Hollis-Eden Pharmaceuticals, Inc. ............................................................................................................................................. 118
    Enzo Biochem, Inc..................................................................................................................................................................... 119
    Genfit ......................................................................................................................................................................................... 120
    Karo Bio..................................................................................................................................................................................... 121
    Ligand Pharmaceuticals Incorporated ....................................................................................................................................... 122
    Lotus Pharmaceuticals, Inc........................................................................................................................................................ 123
    Mesoblast Ltd ............................................................................................................................................................................ 124
    PROLOR Biotech, Inc................................................................................................................................................................ 125
    Oramed Pharmaceuticals, Inc. .................................................................................................................................................. 126
    OXiGENE, Inc............................................................................................................................................................................ 127
    MAP Pharmaceuticals, Inc......................................................................................................................................................... 128


Type 2 Diabetes – Pipeline Review, H1 2012                                                                                                  GMDHC1726IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(3)
Type 2 Diabetes – Pipeline Review, H1 2012




    Lexicon Pharmaceuticals, Inc. ................................................................................................................................................... 129
    BTG International Ltd ................................................................................................................................................................ 130
    Flamel Technologies S.A........................................................................................................................................................... 131
    CombinatoRx, Incorporated ....................................................................................................................................................... 132
    ProteoTech, Inc. ........................................................................................................................................................................ 133
    SANWA KAGAKU KENKYUSHO CO.,LTD. .............................................................................................................................. 134
    Emisphere Technologies, Inc. ................................................................................................................................................... 135
    Repros Therapeutics Inc. .......................................................................................................................................................... 136
    Theratechnologies Inc. .............................................................................................................................................................. 137
    XOMA Ltd. ................................................................................................................................................................................. 138
    Torrent Pharmaceuticals Limited ............................................................................................................................................... 139
    IPCA Laboratories Limited ......................................................................................................................................................... 140
    Lipoxen PLC .............................................................................................................................................................................. 141
    Cytos Biotechnology AG ............................................................................................................................................................ 142
    LG Life Sciences, Ltd ............................................................................................................................................................... 143
    Transition Therapeutics Inc. ...................................................................................................................................................... 144
    DARA BioSciences, Inc. ............................................................................................................................................................ 145
    SemBiosys Genetics Inc............................................................................................................................................................ 146
    Uni-Bio Science Group Ltd. ....................................................................................................................................................... 147
    Summit Corporation plc ............................................................................................................................................................. 148
    OctoPlus N.V. ............................................................................................................................................................................ 149
    DiaMedica Inc. ........................................................................................................................................................................... 150
    Piramal Life Sciences Limited.................................................................................................................................................... 151
    Debiopharm Group .................................................................................................................................................................... 152
    Advinus Therapeutics Pvt. Ltd. .................................................................................................................................................. 153
    Chipscreen Biosciences Ltd ...................................................................................................................................................... 154
    ActogeniX NV ............................................................................................................................................................................ 155
    Camurus AB .............................................................................................................................................................................. 156
    Sirtris Pharmaceuticals, Inc. ...................................................................................................................................................... 157
    Phosphagenics Limited ............................................................................................................................................................. 158
    Domain Therapeutics ................................................................................................................................................................ 159
    7TM Pharma A/S ....................................................................................................................................................................... 160
    Metabolex, Inc ........................................................................................................................................................................... 161
    Spherix Incorporated ................................................................................................................................................................. 162
    Arete Therapeutics Inc. ............................................................................................................................................................. 163
    Arisaph Pharmaceuticals, Inc. ................................................................................................................................................... 164
    AngioChem Inc. ......................................................................................................................................................................... 165
    Allozyne, Inc. ............................................................................................................................................................................. 166
    Metabolic Solutions Development Co. ....................................................................................................................................... 167
    Catabasis Pharmaceuticals, Inc. ............................................................................................................................................... 168
    PhaseBio Pharmaceuticals, Inc. ................................................................................................................................................ 169
    Melior Discovery, Inc. ................................................................................................................................................................ 170
    DiaKine Therapeutics, Inc. ........................................................................................................................................................ 171
    Reata Pharmaceuticals, Inc. ...................................................................................................................................................... 172


Type 2 Diabetes – Pipeline Review, H1 2012                                                                                                GMDHC1726IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                 Page(4)
Type 2 Diabetes – Pipeline Review, H1 2012




    Intarcia Therapeutics, Inc. ......................................................................................................................................................... 173
    Theracos, Inc. ............................................................................................................................................................................ 174
    Versartis, Inc.............................................................................................................................................................................. 175
    Kainos Medicine, Inc. ................................................................................................................................................................ 176
    InteKrin Therapeutics, Inc. ......................................................................................................................................................... 177
    Intercept Pharmaceuticals, Inc. ................................................................................................................................................. 178
    Omeros Corporation .................................................................................................................................................................. 179
    Transtech Pharma, Inc. ............................................................................................................................................................. 180
    BRIDGE BIORESEARCH PLC .................................................................................................................................................. 181
    Peptron, Inc. .............................................................................................................................................................................. 182
    Targacept, Inc............................................................................................................................................................................ 183
    N-Gene Research Laboratories, Inc. ......................................................................................................................................... 184
    Obio Pharmaceutical Holdings Limited. ..................................................................................................................................... 185
    ChemoCentryx, Inc. ................................................................................................................................................................... 186
    VIA Pharmaceuticals, Inc. ......................................................................................................................................................... 187
    Action Pharma A/S .................................................................................................................................................................... 188
    KYORIN Pharmaceutical Co., Ltd.............................................................................................................................................. 189
    Novocell, Inc. ............................................................................................................................................................................. 190
    Verva Pharmaceuticals Limited ................................................................................................................................................. 191
    Napo Pharmaceuticals, Inc. ....................................................................................................................................................... 192
    Exsulin Corporation ................................................................................................................................................................... 193
    Ems Sigma Pharma................................................................................................................................................................... 194
    NasVax Ltd. ............................................................................................................................................................................... 195
    Stelic Institute & Co. .................................................................................................................................................................. 196
    Adamed Sp. z o.o. ..................................................................................................................................................................... 197
    Prosidion Limited ....................................................................................................................................................................... 198
    Amunix, Inc. ............................................................................................................................................................................... 199
    Pharnext SAS ............................................................................................................................................................................ 200
    Nobex Corporation .................................................................................................................................................................... 201
    Diasome Pharmaceuticals, Inc. ................................................................................................................................................. 202
    The Alize Pharma Group ........................................................................................................................................................... 203
    OHR Pharmaceutical Inc. .......................................................................................................................................................... 204
    Heptares Therapeutics Ltd. ....................................................................................................................................................... 205
    Sirona Biochem Corp ................................................................................................................................................................ 206
    XBiotech USA, Inc. .................................................................................................................................................................... 207
    Connexios Life Sciences Pvt. Ltd. ..............................................................................................................
								
To top
;